IQVIA HOLDINGS Q1 FY25 earnings call IQV

The biopharmaceutical sector is experiencing uncertainty due to new U.S. administration initiatives concerning tariffs, agency actions, and drug pricing. This environment has led to delayed decision-making by customers on new programs, with the average time from RFP issuance to award increasing by approximately 10% year-over-year and sequentially. Additionally, the funding environment for emerging biopharma (EBP) companies, particularly early-stage, has deteriorated. Despite these challenges, R&DS demand metrics remain positive, including a record backlog of $31.5 billion and improved RFP flow.

IQVIA's direct exposure to potential industry-specific tariffs is financially immaterial, primarily limited to laboratory supplies. Regarding agency actions, NIH funding caps on indirect costs have no impact on IQVIA, and FDA restructuring has largely preserved core product review teams. Management views FDA Commissioner Makary's focus on AI-based models and enhanced real-world evidence usage as beneficial, potentially accelerating clinical trials and playing to IQVIA's strengths, which is positive for EBP companies.

The U.S. administration's executive order on PBMs, pricing transparency, and Medicare costs is in early stages, with specific impacts yet to be determined. However, two aspects could be positive: the proposal to eliminate the IRA's 'pill penalty' for small molecule drugs (which impacts 50% of a drug's value in years 9-13) and the increased focus on drug pricing, treatment value, and comparative effectiveness, which drives the need for earlier clinical results and more real-world evidence.

Management expressed confidence in the life sciences industry's resilience, highlighting its role as a strategic sector for the U.S. economy, an engine of innovation (responsible for 46% of novel drugs globally over the past decade), and a significant investor in R&D ($200 billion annually). IQVIA's scale, diversification, and portfolio of offerings are seen as key advantages for navigating the current marketplace, with the company believing key decision-makers will ultimately support the sector.

The Technology & Analytics Solutions (TAS) segment continued its strong recovery trend, exceeding expectations with 7.6% constant currency growth. This performance was largely driven by double-digit growth in real-world evidence, which saw pent-up demand return after a period of holding back on discretionary spend. The segment's activities, focused on supporting new drug launches, market access, and commercialization efforts, are considered essential for clients and less susceptible to current macro uncertainties.

While R&DS bookings were softer due to macro uncertainty^🌐, the underlying RFP flow remains robust, particularly from large pharma. The company noted a potential reversal in the trend towards Functional Service Provider (FSP) models, with FSP bookings representing less than 10% of the total in Q1. This suggests a swing back towards full-service outsourcing, driven by clients recognizing the cost and expertise challenges of in-housing more activities.

IQVIA is actively progressing its collaboration with NVIDIA, deploying highly specialized industry AI agents. Over 20 agents are now in production across commercial, real-world, and R&DS use cases, demonstrating positive results. For example, one agentic system in commercial reduced delivery time by two-thirds (from 12 to 4 weeks) and achieved a 30% cost reduction. The company plans to scale to 12 use cases by the end of Q2 and 40 by the end of 2025.